共 204 条
[1]
Anderson WF(2002)Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database Breast Cancer Res Treat 76 27-36
[2]
Chatterjee N(2004)Shifting paradigms in hormonal therapy for breast cancer Cancer Biol Ther 3 797-805
[3]
Ershler WB(2004)Aromatase inhibitors: a new paradigm in breast cancer treatment Curr Med Chem Anticancer Agents 4 523-534
[4]
Brawley OW(2005)Anastrozole: a new gold standard of hormonal treatment for breast cancer? Womens Health (Lond Engl) 1 309-322
[5]
Grana G(2010)Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 509-518
[6]
Narashimamurthy J(2011)Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8 · 1 years median follow-up Lancet Oncol 12 1101-1108
[7]
Rao AR(2010)Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol 11 1135-1141
[8]
Sastry GN(2008)Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network Breast Cancer Res Treat 107 397-403
[9]
Howell A(2009)Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004 Cancer 115 2041-2051
[10]
Dowsett M(2011)Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis J Natl Cancer Inst 103 1299-1309